Andrea Vingiani

Fondazione IRCCS Istituto Nazionale dei Tumori

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (4)

Gabriele Martelli

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Mattia Rediti

Université libre de Bruxelles (ULB)

BELGIUM

View details

Antonino Musolino

Associate Professor

University of Parma

ITALY

View details

Antonia Martinetti

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrea Vingiani

Research Interests

Explore related searches

Contact this professor

Articles (10)

Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients

Advancing breast cancer therapy in the era of molecular diagnostics

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

Clinical and Biological Significance of HER2-Low in Ductal Carcinoma In Situ of the Breast

Detecting gene copy number alterations by Oncomine Comprehensive genomic profiling in a comparative study on FFPE tumor samples

Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study

Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: Real-world observational study

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study

Reliability of core needle biopsy for HER2-low early-stage breast cancer

Collaborators (4)

Gabriele Martelli

Mattia Rediti

Antonino Musolino

Antonia Martinetti

Make your next move.